 |
Skysona overview |
Skysona is a new gene therapy drug from bluebird bio, Inc., for patients living with cerebral adrenoleukodystrophy (CALD), a rare and deadly neurologic disease. Early diagnosis and treatment of CALD is essential because nearly half of patients who do not receive treatment die within five years of symptom onset.*
According to bluebird bio, adrenoleukodystrophy (ALD) is estimated to affect approximately 1 in 20,000 to 1 in 30,000 newborn males. ALD progresses to CALD in approximately 40% of affected boys and in a smaller number of affected men.**
Without Embarc Benefit Protection, the client cost for the one therapeutic required dose of Skysona could be $3 million.*** As of 12/01/2022, we are pleased to include Skysona as part of Embarc Benefit Protection while maintaining our predictable price of $0.99 per member per month (PMPM).
If you have any questions, please contact your Cigna representative.
|